What is the current stock price of Nicox S.A. (NICXF)?

As of the latest market data, Nicox S.A. (NICXF) is trading at $0.30. The stock has seen a gain of 0.00% today.

Does Nicox S.A. (NICXF) pay a dividend?

Based on current data, Nicox S.A. does not have a confirmed active dividend policy.

What is the market cap of Nicox S.A.?

The current market capitalization of Nicox S.A. (NICXF) is approximately unavailable.

NICXF

Nicox S.A.·Healthcare

0.30

0.000%(+0.00)

Close Price

0.33

10.733%(+0.03)

Pre-Market

Last Updated: — ET

52W L: $0.2452W H: $0.44

NICXF NEWS

defenseworld.net

Mar 25

Short Interest in Nicox SA (OTCMKTS:NICXF) Rises By 1,904.8%

Nicox SA (OTCMKTS:NICXF - Get Free Report) was the recipient of a significant growth in short interest in March. As of March 13th, there was short interest totaling 421 shares, a growth of 1,904.8% from the February 26th total of 21 shares. Based on an average daily trading volume, of 0 shares, the short-interest ratio

zacks.com

Mar 9

Nicox (NICXF) Upgraded to Buy: Here's Why

Nicox (NICXF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Company Profile

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating prostaglandin analog for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in phase 3 clinical trial. The company is also developing NCX 4251, a proprietary formulation of fluticasone for acute exacerbations of blepharitis that is in a Phase 2b clinical trial for the treatment of acute exacerbations of blepharitis; and NCX 1728.It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was founded in 1996 and is headquartered in Valbonne, France.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2010-02-22

Beta

0.54

Websitewww.nicox.com↗